The WFH is proud to announce that the 1st World Bleeding Disorders Registry (WBDR) Data Report will be published this summer. The WBDR Data Report...
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...